Please assess the completion status of the following clinical trial:

Trial Title: Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* AML (any type except M3) or CIVIL in blast crisis with greater than or equal to 20% bone marrow blasts at the time of related donor marrow or stem cell transplantation or at relapse post transplant.~* Willing to undergo a skin biopsy and either a leukodepletion apheresis or an additional marrow aspiration.~* Stem cell or marrow donor willing to have apheresis for T-Cell collection.~* Written voluntary informed consent must be obtained from patient and donor.~Exclusion Criteria:~* Medical, social or psychologic factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure.~* AML French-American-British (FAB) subtype M3.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Apheresis + Transplant (Type: EXPERIMENTAL): Skin biopsy \& either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).